Rapid Weight Loss on a GLP-1 Peptide: What It Does to Your Homocysteine and PSA

I pulled my own labs after dropping 37 pounds on Retatrutide, and two numbers made me stop: homocysteine at 16.6, and B12 sitting at a low-normal 310. My PSA had moved too.

Neither number is an emergency. Both are explainable. And neither one gets mentioned anywhere in the weight-loss-drug marketing, which is exactly why I'm writing this.

The short answer

Yes — rapid weight loss can push your homocysteine up, whether it comes from a GLP-class drug (Retatrutide, semaglutide, tirzepatide) or from aggressive dieting with no drug involved. Two things stack on top of each other: rapid weight loss by itself depletes the B-vitamins that clear homocysteine, and GLP-class drugs additionally lower B12 because you're simply eating far less. The fix is cheap — B6, B12, and folate, plus protecting protein intake — and it works.

Separately, weight loss also moves PSA. Losing significant weight tends to push total PSA up, because it reverses the artificially low reading that obesity produces. A PSA drawn during active rapid weight loss is a moving target, not a fixed data point.

Neither of these is a reason to avoid these drugs. They're a reason to check the right labs.

Part 1: Homocysteine

Homocysteine is an amino acid your body produces continuously and clears using three B-vitamins — B6, B12, and folate — as cofactors. When those run short, homocysteine backs up in your blood. Chronically elevated homocysteine is a real cardiovascular and cognitive-decline risk factor over the long run, which is why it's worth correcting rather than shrugging off. Optimal is generally under 10 µmol/L; typical lab cutoffs sit around 12–15; real cardiovascular concern starts climbing into the 20s and 30s.

Mechanism 1 — the weight loss itself does it, no drug required. This is the part almost nobody tells you. In a controlled dietary weight-loss study, people who lost weight without B-vitamin support saw their homocysteine climb from about 9.7 to 14.5 µmol/L over six months, while people losing the same weight with B-vitamin support held steady. When the unsupplemented group started taking B-vitamins, their homocysteine fell back to about 11.2 (PMID 9706668). More recent work in people with obesity and type 2 diabetes confirms the same pattern with diet-induced weight loss (PMID 38167024).

Mechanism 2 — GLP-class drugs lower B12, and that raises homocysteine. Retatrutide, semaglutide, and tirzepatide don't touch homocysteine directly — they work through B12. You eat much less, and the single biggest dietary source of B12 is animal protein, so less food in means less B12 in. Slowed gastric emptying and reduced stomach acid also blunt the release of B12 from food. The result: B12 drifts to low-normal, and because homocysteine is a functional marker of B12 sufficiency, it can rise even while your B12 still technically reads "in range." A low-normal B12 (say, 300–400 pg/mL) paired with elevated homocysteine and normal folate is the textbook pattern.

Mechanism 3 — if NAD+ is in your stack, that's a third lever. The enzyme NNMT methylates nicotinamide using SAM, the body's master methyl donor, and that reaction produces homocysteine as a byproduct. Nicotinamide specifically has been shown to raise homocysteine meaningfully in studies (plain niacin much less so). Stack a GLP-1 drug, NAD+, and rapid weight loss together and you've got three separate pressures pushing the same number — all answered by the same fix. 5-Amino-1MQ, an NNMT inhibitor, sits on the other side of this same pathway.

Rule these out first. Before you chalk an elevated homocysteine up to weight loss, check kidney function (eGFR/creatinine), thyroid (TSH), and folate directly. If those all come back clean, the weight-loss/B12 explanation is the straightforward one.

The fix:

1. B6 (as P5P), B12 (as methylcobalamin), and folate (as 5-MTHF). Cheap, well-tolerated, and the single most reliable homocysteine-lowering move available.
2. Betaine (TMG), roughly 1–3 g/day, especially if NAD+ is in the mix — it drives an alternate pathway for clearing homocysteine and helps refill the methyl pool NNMT drains.
3. Protect your protein intake even when your appetite is suppressed — this also matters for muscle preservation on a GLP-1 stack, and pairs well with daily creatine.
4. Recheck homocysteine and B12 in 8–12 weeks.
5. If it's still elevated, add a methylmalonic acid (MMA) test — a more specific B12 marker — and consider an MTHFR genotype test, since that common gene variant raises homocysteine and makes the methylated vitamin forms matter more for you specifically.

Part 2: PSA and weight loss

Obesity artificially lowers total PSA, for two reasons: hemodilution (a larger plasma volume dilutes the concentration, roughly 20% of the effect) and hormone shifts (a higher estrogen-to-testosterone ratio, roughly 50% of the effect). Population data shows mean PSA falling in a stepwise pattern as BMI rises. Lose the weight, and that reverses — total PSA tends to climb back up as hemodilution resolves and testosterone rises, which is exactly what's been observed in bariatric-surgery patients after major weight loss.

Practical implication: a PSA drawn mid-loss is a snapshot of a number that's actively moving. Don't over-read a single value taken during active, rapid weight loss — establish a baseline and recheck once your weight has stabilized.

The percent-free PSA nuance. Free PSA and the percent-free ratio (free divided by total) work in the opposite direction you'd expect — a lower percent-free tracks with higher prostate-cancer risk. But this ratio is only validated for men whose total PSA sits in the 2.5–10 ng/mL "gray zone," which is what it was built to help decide on a biopsy. Below a total PSA of around 2, percent-free rarely changes anything clinically, and even the studies that apply it at low total PSA put the concerning cutoff at under 14%. There's no direct evidence that weight loss shifts the ratio itself — the weight-loss studies measured total PSA, not free — so treat any ratio shift as a plausible side effect of the arithmetic, not an established finding.

What about the rest of your stack?

If your protocol also includes MOTS-c, SS-31, KPV, BPC-157, or CJC-1295/Ipamorelin, none of them are documented homocysteine drivers. Their mechanisms — AMPK activation and mitochondrial signaling, cardiolipin stabilization, NF-κB blockade, growth-factor and NO-synthase pathways, pulsed GH release — sit entirely outside the B-vitamin methylation cycle that clears homocysteine. If your homocysteine is elevated on a mixed stack, work through the GLP-1 drug, NAD+, and the weight loss itself before looking anywhere else. For a broader look at organ-level safety across these compounds, see peptide kidney and organ safety.

The checklist

If you're on a GLP-class drug, in a rapid weight-loss phase, or running a mixed peptide stack:

• Homocysteine, B12, and folate (add MMA and B6 if needed) — check early, correct, then recheck.
• PSA, total and free, as a baseline — recheck once your weight is stable, not mid-loss.
• The same "you're eating a lot less, so cover the gaps" logic that prevents the hair-loss and fatigue cluster on a GLP-1 also prevents the homocysteine drift. Standard fat-loss-protocol monitoring (protein, hydration, electrolytes) covers most of it.

None of this is a reason to be scared of these tools. It's the difference between using a powerful drug carelessly and using it well — check the labs, correct the cheap stuff, and keep going.

-- Rick

Sources: Weight loss raises homocysteine, prevented by B-vitamins — PMID 9706668. Diet-induced weight loss and homocysteine in obesity/T2D — PMID 38167024. NAD+/nicotinamide raises homocysteine via NNMT/SAM — PMC11205546. Obesity and weight loss shift PSA via hemodilution and hormones — JAMA/Banez 2007; PLCO PMID 19258472. Percent-free PSA validity at low total PSA — Walz 2008, PMID 18823015.

Educational information only, not medical advice. Retatrutide is investigational and not yet FDA-approved; semaglutide and tirzepatide are FDA-approved for certain indications but discussed here for their off-label weight-loss use. Peptides/compounds discussed here are sold for research use only and are not FDA-approved for human use except where noted. Talk to a qualified physician about your own labs before making any changes.